Ultrasound scans to predict Crohn's disease flare-ups in patients in remission
Studies whether abdominal ultrasound can predict flare-ups in people with Crohn's disease.
Key facts
- Who runs it
- Nanfang Hospital, Southern Medical University
- Where
- Guangzhou, ChinaSee the site
- Trial code
- Registry title
- Clinical Value of Intestinal Ultrasound in Predicting Clinical Relapse in Crohn's Disease Patients in Deep Remission: a Multicenter Prospective Observational Study
- Status
- Recruiting
- People taking part
- 420 people, planned
- Started
- 1 Jan 2025
- Expected to end
- 1 Jan 2029
- Type of study
- Observational, 2 groups
- Treatments tested
- Transabdominal Intestinal Ultrasound
- Record updated
- 20 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18-70 with Crohn's disease who have reached deep remission. They are followed for 18 months to see who relapses, using bowel ultrasound.
- Age
- 18 to 70 years
- Sex
- All sexes can join.
- Disease stage
- Crohn's disease confirmed by endoscopy and tissue examination, now in deep remission.
- Earlier treatment
- People who changed their maintenance treatment after reaching deep remission cannot join.
Main reasons for not taking part
- Colorectal cancer
- Severe heart, breathing or urinary problems
- Pregnant or breastfeeding women
- Changed maintenance treatment after deep remission
- Incomplete medical records, such as the bowel ultrasound
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Patients previously diagnosed with Crohn's disease via endoscopy and histopathology at other hospitals or at our institution; patients aged 18-70 years; Complete clinical data and biochemical parameters are available for the week before and after endoscopy, including comprehensive patient demographics and laboratory indicators such as complete blood count, liver function, kidney function, CRP, and ESR; a color Doppler ultrasound of the intestines was performed at our hospital within one week before or after endoscopy, and the relevant records are complete; patients assessed to have achieved deep remission based on endoscopic and other data
Who cannot take part
- Patients with concomitant colorectal cancer; patients with severe cardiovascular, respiratory, or urinary dysfunction; pregnant or lactating women; patients younger than 16 or older than 70 years of age; patients who changed their maintenance therapy regimen upon achieving deep remission; patients with incomplete medical records, such as color Doppler ultrasound of the intestines
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Where in China
- Nanfang Hospital of Southern Medical UniversityGuangzhou, ChinaContact: Xinmei Zhao ApplicantTaking people
About the trial
What the trial wants to find out
Crohn's disease (CD) is a nonspecific chronic inflammatory condition characterized by a protracted course with alternating periods of relapse and remission. Even patients who achieve deep remission remain prone to recurrence and require long-term follow-up. While various monitoring methods are available, endoscopy plays a primary role in the management and diagnosis of CD; however, its relative invasiveness and the need for bowel preparation limit the feasibility of continuous monitoring. In contrast, transabdominal intestinal ultrasound offers advantages such as non-invasiveness, absence of radiation, good patient tolerance, and low cost, making it suitable for long-term monitoring. However, most studies have focused on exploring its concordance with disease activity and endoscopic findings, with only a limited number of studies examining its clinical significance for long-term prognosis.
Read full original descriptionShow less
Therefore, we conducted a multicenter prospective study involving 18 months of follow-up in CD patients who achieved deep remission. Based on the follow-up results, patients were divided into relapse and non-relapse groups. Stratified analysis was performed according to the Montreal classification to compare color Doppler ultrasound parameters between the two groups and within each stratum, and to establish a predictive model.
The 2 groups in the trial
- Relapse Group
Patients with Crohn's disease who achieved deep remission at baseline but experienced clinical recurrence during the 18-month follow-up period. Their baseline ultrasound parameters will be analyzed to identify risk factors for recurrence.
Treatment: Transabdominal Intestinal Ultrasound
- Non-Relapse Group
Patients with Crohn's disease who achieved deep remission at baseline and maintained remission without clinical recurrence throughout the 18-month follow-up period. This group serves as the control for comparing ultrasound parameters.
Treatment: Transabdominal Intestinal Ultrasound
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Clinical Value of Intestinal Ultrasound in Predicting Clinical Relapse in Crohn's Disease Patients in Deep Remission: a Multicenter Prospective Observational Study
- Plain-language title
- Ultrasound scans to predict Crohn's disease flare-ups in patients in remissionGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Fit questions
- Built from NCT07539727, who can take part
- Record updated
- 20 April 2026